The addition of preoperative chemotherapy may eradicate micrometastatic disease and direct postoperative therapy in the case of resistance.
After the initial year of follow-up, 2 patients in the standard arm and 1 patient in the re-curettage arm had relapsed.
While checks were documented thoroughly in 3 centers, there were no internal standards for physician checks.
Metronomic Chemotherapy May Improve Outcomes Among Elderly Patients With HER2-Positive Breast CancerFebruary 12, 2018
Researchers evaluated whether dual HER2 inhibition with trastuzumab and pertuzumab plus metronomic cyclophosphamide is superior to dual HER2 inhibition alone.
DS-8201 is an investigational HER2-targeting ADC, a targeted therapy for cancer that delivers cytotoxic chemotherapy by means of a linker on the monoclonal antibody that attaches to a specific target on cancer cells.
Patients with triple-negative breast cancer without BRCA1 and BRCA2 germline mutations may benefit from the addition of carboplatin to a chemotherapy regimen.
Adding evofosfamide to doxorubicin is not recommended as a first-line treatment for patients with advanced soft-tissue sarcoma.
Once-daily radiotherapy is not superior to twice-daily treatment for patients with small-cell lung cancer receiving concurrent chemoradiotherapy.
Among patients suffering post-radiation or chemoradiation locoregional HNSCC recurrence, those with HPV-positive disease may have better survival rates.
A standard chemotherapy regimen was more efficacious than histotype-guided chemotherapy among patients with high-risk, localized sarcoma of the extremities or trunk wall.
A review of treatment options for patients experiencing chemotherapy- cr radiation-induced nausea and vomiting.
Many patients who receive chemotherapy or radiotherapy as a part of their treatment for cancer develop oral mucositis, which is a painful, debilitating condition.
Patients who reported better clinician communication or an improved satisfaction with their treatment were more likely to be adherent.
This study indicates that there is no difference in efficacy or safety between aprepitant and fosaprepitant, though the study was limited by its small sample size.
Study authors conclude that FLOT should be an internationally standard option for patients with resectable gastric cancer.
Adding ramucirumab to mFOLFOX6 therapy in an intent-to-treat population of patients with GEJ does not improve PFS.
Dopamine antagonist olanzapine prevents nausea and the complete response rate among previously untreated patients receiving highly emetogenic chemotherapy.
TAS-102 improved survival, when contrasted with placebo, for patients with refractory colorectal cancer, though the drug showed no activity for the second-line treatment of patients with small cell lung cancer.
Neratinib demonstrated clinical efficacy for patients with HER2-positive, hormone-receptor-negative breast cancer, in a phase 2 study.
Males with breast cancer are less likely to survive than females after disease recurrence, which may be due to less aggressive treatment after relapse.
Carfilzomib is superior to bortezomib for progression-free survival, regardless of previous treatments or prior exposure to either bortezomib or lenalidomide, for patients with multiple myeloma.
The combination of ixazomib, cyclophosphamide, and dexamethasone induced high response rates with good tolerability in patients with newly-diagnosed multiple myeloma.
Adjuvant chemotherapy with S-1 may improve standard of care for Japanese patients with resected pancreatic cancer.
Addition of olaratumab to doxorubicin significantly improves PFS and OS in patients with advanced soft-tissue sarcoma.
Gemcitabine Plus Capecitabine More Effective for Treatment of Pancreatic Cancer Than Gemcitabine AloneJune 06, 2016
Gemcitabine plus capecitabine improves survival for patients with pancreatic cancer
First-line FOLFIRINOX treatment appears to result in a higher overall survival in patients with advanced pancreatic cancer.
Identifying HER2-pathway cancer "addicts," omitting adjuvant chemotherapy based on a 21-gene Recurrence Score, and improving survival with dose-dense chemotherapy were among the treatment topics highlighted.
The addition of ramucirumab to docetaxel improved clinical efficacy outcomes, without decreasing quality of life in non-small cell lung cancer.
The addition of ramucirumab to paclitaxel for treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma increased overall survival.
Nanoliposomal Irinotecan + Fluorouracil and Folinic Acid Extends Overall Survival in Patients with Metastatic Pancreatic CancerJanuary 06, 2016
Nanoliposomal irinotecan plus fluorouracil and folinic acid extends survival in patients with metastatic pancreatic cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Resveratrol and Cancer
- Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
- Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
- ARID1A Mutations Might Predict Tumor Response to Immunotherapy
- Global Burden of Myeloma Increasing, Access to Treatments Lacking
- ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks
- Adding Rituximab to Prednisolone May Improve Long-Term Response in Immune Thrombocytopenia
- FDA Updates Restrictions for Pembrolizumab, Atezolizumab in Urothelial Carcinoma
- Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
- Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer